{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"17.8","upperLimit":"33.4","value":"25.6"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"121"}],"units":"Participants"}],"description":"Distant failure was defined as the interval from end of RT to date of distant failure (or combined local + distant failure). Competing events were local failure or second malignancy. Patients without an event were censored at date of last contact. The 1-year cumulative incidence was estimated and reported with a 95% confidence interval.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients with M0 medulloblastoma or nodular desmoplastic histology with less than a GTR, other histologic diagnoses with no metastatic disease who received induction chemotherapy and intermediate-risk therapy that included focal radiation.","id":"OG000","title":"Intermediate-risk Patients Who Received Focal Radiation"}],"paramType":"NUMBER","populationDescription":"Eligible intermediate-risk patients who received focal radiation were included in this analysis. Of the 156 intermediate risk patients, 121 started radiation.","reportingStatus":"POSTED","timeFrame":"1 year after completion of radiation therapy for last patient","title":"Rate of Distant Disease Progression","type":"SECONDARY","unitOfMeasure":"percentage of participants"}